Showing 20 of 64 recruiting trials for “angiocentric-glioma”
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
RecruitingNCT07236840 ↗
Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors
RecruitingNCT07240662 ↗
Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma
RecruitingNCT07405372 ↗
Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
👨⚕️ Sabine Mueller, MD, PHD, University of California, San Francisco📍 4 sites📅 Started Nov 2025View details ↗
A Study of 177Lu-PSMA-617 in People With Gliomas
👨⚕️ Brandon Imber, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Oct 2025View details ↗
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
👨⚕️ Robert Press, M.D., Miami Cancer Institute at Baptist Health, Inc.📍 2 sites📅 Started Apr 2025View details ↗
Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
👨⚕️ Andrew J Brenner, PhD, The Cancer Therapy and Research Center at UTHSCSA📍 1 site📅 Started Dec 2024View details ↗
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
🏥 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 1 site📅 Started Oct 2024View details ↗
Enrolling by InvitationNCT07450040 ↗
Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
RecruitingNCT06546631 ↗
Investigating Mechanistic Predictors of Interpatient Variability and Temozolomide (TMZ) Induced Haematological Toxicity for Glioma Patients
18F-Fluciclovine PET-MRI in High-grade Glioma
👨⚕️ Mariam Aboian, MD,PhD, Children's Hospital of Philadelphia📍 1 site📅 Started Aug 2024View details ↗
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
RecruitingNCT06180434 ↗
Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas
👨⚕️ Alejandra Mendez Romero, MD PhD, Assitant Professor, Radiation Oncologist📍 1 site📅 Started May 2024View details ↗
Page 1 of 4Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →